Meta-analysis on safety and efficacy of liposomal amphotericin B in the empirical treatment of febrile neutropenia;Metaanálisis de la seguridad y eficacia de la anfotericina B liposómica en el tratamiento empírico de la neutropenia febril

Medicina Clinica

Volumn 122, Issue 16, 2004, Pages 610-616

  Badia, Xavier ^a,b   Roset, Montserrat ^a   Carreras, Enric ^c   Ausin, Inmaculada ^d   Herrera, Luis ^d  

^a Health Outcomes Research Europe   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d Gilead Sciences   (Spain)

Author keywords

Amphotericin B; Empirical treatment; Febrile neutropenia; Liposomal amphotericin B; Meta analysis; Voriconazol

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; VORICONAZOLE;

ARTICLE; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EMBASE; FEBRILE NEUTROPENIA; FEVER; HUMAN; MEDLINE; MORTALITY; NEPHROTOXICITY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VOMITING;

EID: 2542575672     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13061071     Document Type: Article

References (23)

1. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-11.
2. Richardson MD, Kokki MH. Antifungal therapy in «bone marrow failure». Br J Haematol 1998; 100:619-28.
3. Warnock DW. Fungal infections in neutropenia: current problems and chemotherapeutic control. J Antimicrob Chemother 1998;41(Suppl D):95-105.
4. Hughes WT, Armstrong D, Bodey GP. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51.
5. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000;30:662-78.
6. Richardson MD, Kokki MH. New perspectives in the diagnosis of systemic fungal infections. Ann Med 1999;31:327-35.
7. Pizzo PA. Management of fever in patients cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323-32.
8. Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997;98:711-8.
9. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomial amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340:764-71.
10. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999;12:40-79.
11. Hossain MA, Ghannoum MA. New investigational antifungal agents for treating invasive fungal infections. Expert Opin Investig Drugs 2000;9: 1797-813.
12. Malik IA, Moid I, Aziz Z, Khan S, Suleman M. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 1998;105:478-83.
13. Viscoli C, Castagnola E, Van Lint MT, Moroni C, Garaventa A, Rossi MR, et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomized clinical trial. Eur J Cancer 1996;32A:814-20.
14. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000;108:282-9.
15. Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: a randomized, controlled trial. Ann Intern Med 2001;135:412-22.
16. th Annual Meeting of the Infectious Diseases Society of America; 2000, September 7-10; New Orleans.
17. th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000, September 17-20, Toronto.
18. th Annual Meeting of the Infectious Diseases Society of America; 2000, September 7-10; New Orleans.
19. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, et al. Voriconazole compared with liposomial amphotericin B for empirical anti-fungal therapy in patients with neutropenia and persistent fewer. N Engl J Med 2002;346:225-34.
20. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A, and the L Amph/ABCL Collaborative Study Group. A randomized, double-blind comparative trial evaluating the safety of liposomial amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. CID 2000;31:1155-63.
21. Marr KA. Empirical antifungal therapy - New options, new tradeoffs. N Engl J Med 2002;346: 278-80.
22. Fischer T, Heussel G, Huber C. Liposomial amphotericin B for fever and neutropenia. N Engl J Med 1999;341:1152-5.
23. Powers JH, Dixon CA, Goldberger MJ. Voriconazol versus liposomial amphotericin B in patients with neutropenia and persistent fever. N Engl J Med 2002;346:289-90.